SOC Update accepts submissions from:

• Practicing Dermatologists
• Analysts
• Consultants
• Dermatology Residents
• Healthcare Providers
• Industry
• Dermatology Fellows
• Researchers

Submitting parties receive automatic notification that the poster submission has been received. However, due to the high volume of submissions, additional acknowledgement may not be sent unless the poster is accepted by the review committee.

Abstract Submission Deadline: August 2, 2024

Notification Date: August 9, 2024

Fee: No fee for non-industry-sponsored abstracts; $495 per abstract for industry-sponsored abstracts.

In order to display your poster at the meeting, one author or representative is required to register for Skin of Color Update. To view registration pricing and to register for the event, click here.

All accepted posters will be displayed at the Skin of Color Update, September 13-15, 2024, to be held at the New York Hilton Midtown, New York, NY.

In addition, approved abstracts will also be submitted and indexed through our partner brand Read by QxMD. The platform drives awareness, dissemination and engagement with this content via the Read by QxMD platform, as an educational tactic to drive CQI. ‘Read’ works on iPhone, iPad, Android smartphones & tablets and any web-enabled device (including desktops), and uses channels such as mobile, email and push notification to connect with our global community of healthcare providers and researchers.

If you are returning to complete or check the status of your submission, please sign-in HERE using your email address and password. 

Encore posters are welcome! 

Abstract Formatting and Content Guidelines 

• Language: English  
• Authors: full last name, first name, affiliations, degrees and contact information 

• • BOLD the name of the Presenting Author and include the Presenting Author’s contact information  

• Font: Arial 
• Maximum of 3000 characters, including spaces (not including the title, authors, or affiliations) 
• Maximum of 2 relevant tables or figures submitted as attachments (not embedded in the file): must be 600 dpi .jpg  
• Author(s) disclosures must be included to be considered. 
• References must be included as parenthetical in-text citations – first author, et al, journal and year – (Cruz D, et al. Blood 2012) 
• Full contact information of corresponding author (Please ensure that your email address is accurate, as all correspondence will be sent via email)  
• Abstract text should preferably be in a “structured abstract” form with sections marked Background, Objectives, Methods, Results, Disclosures and Conclusions. 
• Abstracts containing non-generic drug names or personal patient information, or reporting studies with unidentified chemical compounds, drugs, or materials, will not be accepted. 

Please note that abstracts will not be accepted if the presenting author’s name is not bolded, presenting author’s email is not included and all faculty disclosures are not listed. 

If you have any questions, please contact Berenice Bonalanza at [email protected]